nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ABCB1—esophageal cancer	0.363	1	CbGaD
Fluoxetine—CYP2C9—Capecitabine—esophageal cancer	0.0532	0.258	CbGbCtD
Fluoxetine—CYP2B6—Cisplatin—esophageal cancer	0.0507	0.246	CbGbCtD
Fluoxetine—ALB—Methotrexate—esophageal cancer	0.0323	0.157	CbGbCtD
Fluoxetine—CYP2C9—Cisplatin—esophageal cancer	0.0268	0.13	CbGbCtD
Fluoxetine—ABCB1—Cisplatin—esophageal cancer	0.026	0.126	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—esophageal cancer	0.0169	0.082	CbGbCtD
Fluoxetine—HTR2A—vagus nerve—esophageal cancer	0.00103	0.169	CbGeAlD
Fluoxetine—Coma—Methotrexate—esophageal cancer	0.000457	0.00171	CcSEcCtD
Fluoxetine—Dehydration—Capecitabine—esophageal cancer	0.000453	0.0017	CcSEcCtD
Fluoxetine—Neoplasm—Methotrexate—esophageal cancer	0.000452	0.00169	CcSEcCtD
Fluoxetine—Ecchymosis—Methotrexate—esophageal cancer	0.000452	0.00169	CcSEcCtD
Fluoxetine—Urine output increased—Methotrexate—esophageal cancer	0.000452	0.00169	CcSEcCtD
Fluoxetine—Mouth ulceration—Methotrexate—esophageal cancer	0.000452	0.00169	CcSEcCtD
Fluoxetine—Bladder pain—Methotrexate—esophageal cancer	0.000452	0.00169	CcSEcCtD
Fluoxetine—Liver function test abnormal—Capecitabine—esophageal cancer	0.00045	0.00169	CcSEcCtD
Fluoxetine—Gynaecomastia—Methotrexate—esophageal cancer	0.000447	0.00167	CcSEcCtD
Fluoxetine—Dry skin—Capecitabine—esophageal cancer	0.000447	0.00167	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000445	0.00167	CcSEcCtD
Fluoxetine—Pulmonary oedema—Methotrexate—esophageal cancer	0.000445	0.00167	CcSEcCtD
Fluoxetine—Hypokalaemia—Capecitabine—esophageal cancer	0.000444	0.00166	CcSEcCtD
Fluoxetine—Visual impairment—Cisplatin—esophageal cancer	0.000441	0.00165	CcSEcCtD
Fluoxetine—Breast disorder—Capecitabine—esophageal cancer	0.000441	0.00165	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000439	0.00164	CcSEcCtD
Fluoxetine—Gastritis—Capecitabine—esophageal cancer	0.000432	0.00162	CcSEcCtD
Fluoxetine—Muscular weakness—Capecitabine—esophageal cancer	0.00043	0.00161	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00043	0.00161	CcSEcCtD
Fluoxetine—Tinnitus—Cisplatin—esophageal cancer	0.000427	0.0016	CcSEcCtD
Fluoxetine—Lymphadenopathy—Methotrexate—esophageal cancer	0.000425	0.00159	CcSEcCtD
Fluoxetine—Abdominal distension—Capecitabine—esophageal cancer	0.000424	0.00159	CcSEcCtD
Fluoxetine—Influenza—Capecitabine—esophageal cancer	0.000421	0.00158	CcSEcCtD
Fluoxetine—Asthma—Capecitabine—esophageal cancer	0.000421	0.00158	CcSEcCtD
Fluoxetine—Dysphagia—Capecitabine—esophageal cancer	0.000421	0.00158	CcSEcCtD
Fluoxetine—Thrombophlebitis—Methotrexate—esophageal cancer	0.000419	0.00157	CcSEcCtD
Fluoxetine—Diabetes mellitus—Methotrexate—esophageal cancer	0.000417	0.00156	CcSEcCtD
Fluoxetine—Bronchospasm—Capecitabine—esophageal cancer	0.000415	0.00155	CcSEcCtD
Fluoxetine—Polyuria—Methotrexate—esophageal cancer	0.000413	0.00155	CcSEcCtD
Fluoxetine—Angina pectoris—Capecitabine—esophageal cancer	0.000411	0.00154	CcSEcCtD
Fluoxetine—Sweating increased—Capecitabine—esophageal cancer	0.000411	0.00154	CcSEcCtD
Fluoxetine—Arrhythmia—Cisplatin—esophageal cancer	0.000409	0.00153	CcSEcCtD
Fluoxetine—Bronchitis—Capecitabine—esophageal cancer	0.000405	0.00152	CcSEcCtD
Fluoxetine—Alopecia—Cisplatin—esophageal cancer	0.000404	0.00151	CcSEcCtD
Fluoxetine—Hepatic failure—Methotrexate—esophageal cancer	0.000404	0.00151	CcSEcCtD
Fluoxetine—Pancytopenia—Capecitabine—esophageal cancer	0.0004	0.0015	CcSEcCtD
Fluoxetine—Malnutrition—Cisplatin—esophageal cancer	0.000398	0.00149	CcSEcCtD
Fluoxetine—Dysuria—Capecitabine—esophageal cancer	0.000394	0.00148	CcSEcCtD
Fluoxetine—Flatulence—Cisplatin—esophageal cancer	0.000393	0.00147	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000392	0.00147	CcSEcCtD
Fluoxetine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000385	0.00144	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000385	0.00144	CcSEcCtD
Fluoxetine—Weight increased—Capecitabine—esophageal cancer	0.000384	0.00144	CcSEcCtD
Fluoxetine—Muscle spasms—Cisplatin—esophageal cancer	0.000383	0.00143	CcSEcCtD
Fluoxetine—Weight decreased—Capecitabine—esophageal cancer	0.000381	0.00143	CcSEcCtD
Fluoxetine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00038	0.00142	CcSEcCtD
Fluoxetine—Pneumonia—Capecitabine—esophageal cancer	0.000378	0.00141	CcSEcCtD
Fluoxetine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000375	0.0014	CcSEcCtD
Fluoxetine—Depression—Capecitabine—esophageal cancer	0.000375	0.0014	CcSEcCtD
Fluoxetine—Tremor—Cisplatin—esophageal cancer	0.000373	0.0014	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000373	0.00139	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00037	0.00139	CcSEcCtD
Fluoxetine—Lethargy—Methotrexate—esophageal cancer	0.00037	0.00139	CcSEcCtD
Fluoxetine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00037	0.00139	CcSEcCtD
Fluoxetine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00037	0.00138	CcSEcCtD
Fluoxetine—Renal failure—Capecitabine—esophageal cancer	0.000369	0.00138	CcSEcCtD
Fluoxetine—Myocardial infarction—Capecitabine—esophageal cancer	0.000368	0.00138	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000368	0.00138	CcSEcCtD
Fluoxetine—Anaemia—Cisplatin—esophageal cancer	0.000368	0.00138	CcSEcCtD
Fluoxetine—Stomatitis—Capecitabine—esophageal cancer	0.000366	0.00137	CcSEcCtD
Fluoxetine—Jaundice—Capecitabine—esophageal cancer	0.000366	0.00137	CcSEcCtD
Fluoxetine—Conjunctivitis—Capecitabine—esophageal cancer	0.000365	0.00137	CcSEcCtD
Fluoxetine—Urinary tract infection—Capecitabine—esophageal cancer	0.000365	0.00137	CcSEcCtD
Fluoxetine—Osteoarthritis—Methotrexate—esophageal cancer	0.000363	0.00136	CcSEcCtD
Fluoxetine—Malaise—Cisplatin—esophageal cancer	0.000359	0.00134	CcSEcCtD
Fluoxetine—Haematuria—Capecitabine—esophageal cancer	0.000358	0.00134	CcSEcCtD
Fluoxetine—Leukopenia—Cisplatin—esophageal cancer	0.000357	0.00133	CcSEcCtD
Fluoxetine—Epistaxis—Capecitabine—esophageal cancer	0.000354	0.00133	CcSEcCtD
Fluoxetine—Irritability—Methotrexate—esophageal cancer	0.000346	0.0013	CcSEcCtD
Fluoxetine—Convulsion—Cisplatin—esophageal cancer	0.000345	0.00129	CcSEcCtD
Fluoxetine—Mood swings—Methotrexate—esophageal cancer	0.000344	0.00129	CcSEcCtD
Fluoxetine—Bradycardia—Capecitabine—esophageal cancer	0.000343	0.00129	CcSEcCtD
Fluoxetine—Ataxia—Methotrexate—esophageal cancer	0.000341	0.00128	CcSEcCtD
Fluoxetine—Myalgia—Cisplatin—esophageal cancer	0.000339	0.00127	CcSEcCtD
Fluoxetine—Haemoglobin—Capecitabine—esophageal cancer	0.000339	0.00127	CcSEcCtD
Fluoxetine—Rhinitis—Capecitabine—esophageal cancer	0.000338	0.00127	CcSEcCtD
Fluoxetine—Anxiety—Cisplatin—esophageal cancer	0.000338	0.00127	CcSEcCtD
Fluoxetine—Hepatitis—Capecitabine—esophageal cancer	0.000337	0.00126	CcSEcCtD
Fluoxetine—Haemorrhage—Capecitabine—esophageal cancer	0.000337	0.00126	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000337	0.00126	CcSEcCtD
Fluoxetine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000336	0.00126	CcSEcCtD
Fluoxetine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000335	0.00125	CcSEcCtD
Fluoxetine—Discomfort—Cisplatin—esophageal cancer	0.000335	0.00125	CcSEcCtD
Fluoxetine—Pharyngitis—Capecitabine—esophageal cancer	0.000335	0.00125	CcSEcCtD
Fluoxetine—Oedema peripheral—Capecitabine—esophageal cancer	0.000332	0.00124	CcSEcCtD
Fluoxetine—Breast disorder—Methotrexate—esophageal cancer	0.000328	0.00123	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000327	0.00122	CcSEcCtD
Fluoxetine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000325	0.00122	CcSEcCtD
Fluoxetine—Visual impairment—Capecitabine—esophageal cancer	0.000325	0.00122	CcSEcCtD
Fluoxetine—Infection—Cisplatin—esophageal cancer	0.000323	0.00121	CcSEcCtD
Fluoxetine—Erythema multiforme—Capecitabine—esophageal cancer	0.000319	0.00119	CcSEcCtD
Fluoxetine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000318	0.00119	CcSEcCtD
Fluoxetine—Tachycardia—Cisplatin—esophageal cancer	0.000317	0.00119	CcSEcCtD
Fluoxetine—Skin disorder—Cisplatin—esophageal cancer	0.000316	0.00118	CcSEcCtD
Fluoxetine—Tinnitus—Capecitabine—esophageal cancer	0.000314	0.00118	CcSEcCtD
Fluoxetine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000314	0.00118	CcSEcCtD
Fluoxetine—Asthma—Methotrexate—esophageal cancer	0.000314	0.00117	CcSEcCtD
Fluoxetine—Eosinophilia—Methotrexate—esophageal cancer	0.000311	0.00116	CcSEcCtD
Fluoxetine—Anorexia—Cisplatin—esophageal cancer	0.00031	0.00116	CcSEcCtD
Fluoxetine—Pancreatitis—Methotrexate—esophageal cancer	0.000308	0.00115	CcSEcCtD
Fluoxetine—Hypotension—Cisplatin—esophageal cancer	0.000304	0.00114	CcSEcCtD
Fluoxetine—Chills—Capecitabine—esophageal cancer	0.000303	0.00113	CcSEcCtD
Fluoxetine—Arrhythmia—Capecitabine—esophageal cancer	0.000301	0.00113	CcSEcCtD
Fluoxetine—Alopecia—Capecitabine—esophageal cancer	0.000298	0.00112	CcSEcCtD
Fluoxetine—Pancytopenia—Methotrexate—esophageal cancer	0.000298	0.00112	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000296	0.00111	CcSEcCtD
Fluoxetine—Mental disorder—Capecitabine—esophageal cancer	0.000296	0.00111	CcSEcCtD
Fluoxetine—Malnutrition—Capecitabine—esophageal cancer	0.000294	0.0011	CcSEcCtD
Fluoxetine—Dysuria—Methotrexate—esophageal cancer	0.000293	0.0011	CcSEcCtD
Fluoxetine—Paraesthesia—Cisplatin—esophageal cancer	0.000292	0.00109	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000292	0.00109	CcSEcCtD
Fluoxetine—Dyspnoea—Cisplatin—esophageal cancer	0.00029	0.00108	CcSEcCtD
Fluoxetine—Flatulence—Capecitabine—esophageal cancer	0.000289	0.00108	CcSEcCtD
Fluoxetine—Erectile dysfunction—Methotrexate—esophageal cancer	0.000289	0.00108	CcSEcCtD
Fluoxetine—Dysgeusia—Capecitabine—esophageal cancer	0.000288	0.00108	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000286	0.00107	CcSEcCtD
Fluoxetine—SIGMAR1—bronchus—esophageal cancer	0.000285	0.0465	CbGeAlD
Fluoxetine—Back pain—Capecitabine—esophageal cancer	0.000284	0.00106	CcSEcCtD
Fluoxetine—Decreased appetite—Cisplatin—esophageal cancer	0.000283	0.00106	CcSEcCtD
Fluoxetine—Muscle spasms—Capecitabine—esophageal cancer	0.000282	0.00106	CcSEcCtD
Fluoxetine—Pneumonia—Methotrexate—esophageal cancer	0.000281	0.00105	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000281	0.00105	CcSEcCtD
Fluoxetine—Drowsiness—Methotrexate—esophageal cancer	0.00028	0.00105	CcSEcCtD
Fluoxetine—SIGMAR1—smooth muscle tissue—esophageal cancer	0.000279	0.0455	CbGeAlD
Fluoxetine—Depression—Methotrexate—esophageal cancer	0.000279	0.00104	CcSEcCtD
Fluoxetine—Pain—Cisplatin—esophageal cancer	0.000278	0.00104	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000277	0.00104	CcSEcCtD
Fluoxetine—Tremor—Capecitabine—esophageal cancer	0.000275	0.00103	CcSEcCtD
Fluoxetine—Renal failure—Methotrexate—esophageal cancer	0.000275	0.00103	CcSEcCtD
Fluoxetine—Stomatitis—Methotrexate—esophageal cancer	0.000273	0.00102	CcSEcCtD
Fluoxetine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000272	0.00102	CcSEcCtD
Fluoxetine—Conjunctivitis—Methotrexate—esophageal cancer	0.000272	0.00102	CcSEcCtD
Fluoxetine—Anaemia—Capecitabine—esophageal cancer	0.000271	0.00102	CcSEcCtD
Fluoxetine—Sweating—Methotrexate—esophageal cancer	0.000268	0.001	CcSEcCtD
Fluoxetine—Feeling abnormal—Cisplatin—esophageal cancer	0.000268	0.001	CcSEcCtD
Fluoxetine—Haematuria—Methotrexate—esophageal cancer	0.000267	0.000998	CcSEcCtD
Fluoxetine—Malaise—Capecitabine—esophageal cancer	0.000265	0.000991	CcSEcCtD
Fluoxetine—Epistaxis—Methotrexate—esophageal cancer	0.000264	0.000988	CcSEcCtD
Fluoxetine—Vertigo—Capecitabine—esophageal cancer	0.000264	0.000988	CcSEcCtD
Fluoxetine—Syncope—Capecitabine—esophageal cancer	0.000263	0.000986	CcSEcCtD
Fluoxetine—Leukopenia—Capecitabine—esophageal cancer	0.000263	0.000984	CcSEcCtD
Fluoxetine—Palpitations—Capecitabine—esophageal cancer	0.000259	0.000971	CcSEcCtD
Fluoxetine—Loss of consciousness—Capecitabine—esophageal cancer	0.000258	0.000966	CcSEcCtD
Fluoxetine—Body temperature increased—Cisplatin—esophageal cancer	0.000257	0.000962	CcSEcCtD
Fluoxetine—SIGMAR1—trachea—esophageal cancer	0.000256	0.0417	CbGeAlD
Fluoxetine—Cough—Capecitabine—esophageal cancer	0.000256	0.000959	CcSEcCtD
Fluoxetine—Hypertension—Capecitabine—esophageal cancer	0.000254	0.000949	CcSEcCtD
Fluoxetine—Haemoglobin—Methotrexate—esophageal cancer	0.000252	0.000945	CcSEcCtD
Fluoxetine—Haemorrhage—Methotrexate—esophageal cancer	0.000251	0.00094	CcSEcCtD
Fluoxetine—Hepatitis—Methotrexate—esophageal cancer	0.000251	0.00094	CcSEcCtD
Fluoxetine—Myalgia—Capecitabine—esophageal cancer	0.00025	0.000936	CcSEcCtD
Fluoxetine—Chest pain—Capecitabine—esophageal cancer	0.00025	0.000936	CcSEcCtD
Fluoxetine—Arthralgia—Capecitabine—esophageal cancer	0.00025	0.000936	CcSEcCtD
Fluoxetine—Pharyngitis—Methotrexate—esophageal cancer	0.000249	0.000933	CcSEcCtD
Fluoxetine—Anxiety—Capecitabine—esophageal cancer	0.000249	0.000933	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000248	0.000929	CcSEcCtD
Fluoxetine—Discomfort—Capecitabine—esophageal cancer	0.000247	0.000925	CcSEcCtD
Fluoxetine—Dry mouth—Capecitabine—esophageal cancer	0.000244	0.000915	CcSEcCtD
Fluoxetine—Visual impairment—Methotrexate—esophageal cancer	0.000242	0.000906	CcSEcCtD
Fluoxetine—Confusional state—Capecitabine—esophageal cancer	0.000242	0.000905	CcSEcCtD
Fluoxetine—Hypersensitivity—Cisplatin—esophageal cancer	0.00024	0.000897	CcSEcCtD
Fluoxetine—Infection—Capecitabine—esophageal cancer	0.000238	0.000891	CcSEcCtD
Fluoxetine—Erythema multiforme—Methotrexate—esophageal cancer	0.000237	0.000889	CcSEcCtD
Fluoxetine—Shock—Capecitabine—esophageal cancer	0.000236	0.000883	CcSEcCtD
Fluoxetine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000235	0.000878	CcSEcCtD
Fluoxetine—Tinnitus—Methotrexate—esophageal cancer	0.000234	0.000876	CcSEcCtD
Fluoxetine—Tachycardia—Capecitabine—esophageal cancer	0.000234	0.000876	CcSEcCtD
Fluoxetine—Asthenia—Cisplatin—esophageal cancer	0.000233	0.000873	CcSEcCtD
Fluoxetine—Skin disorder—Capecitabine—esophageal cancer	0.000233	0.000871	CcSEcCtD
Fluoxetine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000232	0.000867	CcSEcCtD
Fluoxetine—Anorexia—Capecitabine—esophageal cancer	0.000228	0.000855	CcSEcCtD
Fluoxetine—HTR2A—neck—esophageal cancer	0.000227	0.037	CbGeAlD
Fluoxetine—Chills—Methotrexate—esophageal cancer	0.000225	0.000843	CcSEcCtD
Fluoxetine—Hypotension—Capecitabine—esophageal cancer	0.000224	0.000838	CcSEcCtD
Fluoxetine—Diarrhoea—Cisplatin—esophageal cancer	0.000222	0.000833	CcSEcCtD
Fluoxetine—SLC6A4—digestive system—esophageal cancer	0.000222	0.0362	CbGeAlD
Fluoxetine—Alopecia—Methotrexate—esophageal cancer	0.000222	0.000831	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—esophageal cancer	0.00022	0.000823	CcSEcCtD
Fluoxetine—Malnutrition—Methotrexate—esophageal cancer	0.000219	0.000818	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000218	0.000817	CcSEcCtD
Fluoxetine—ORM1—lung—esophageal cancer	0.000218	0.0354	CbGeAlD
Fluoxetine—Insomnia—Capecitabine—esophageal cancer	0.000217	0.000811	CcSEcCtD
Fluoxetine—Paraesthesia—Capecitabine—esophageal cancer	0.000215	0.000806	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—esophageal cancer	0.000214	0.000801	CcSEcCtD
Fluoxetine—Dyspnoea—Capecitabine—esophageal cancer	0.000214	0.0008	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—esophageal cancer	0.000211	0.000791	CcSEcCtD
Fluoxetine—Dyspepsia—Capecitabine—esophageal cancer	0.000211	0.00079	CcSEcCtD
Fluoxetine—Decreased appetite—Capecitabine—esophageal cancer	0.000208	0.00078	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000207	0.000774	CcSEcCtD
Fluoxetine—Vomiting—Cisplatin—esophageal cancer	0.000207	0.000774	CcSEcCtD
Fluoxetine—Fatigue—Capecitabine—esophageal cancer	0.000207	0.000773	CcSEcCtD
Fluoxetine—Rash—Cisplatin—esophageal cancer	0.000205	0.000767	CcSEcCtD
Fluoxetine—Pain—Capecitabine—esophageal cancer	0.000205	0.000767	CcSEcCtD
Fluoxetine—Constipation—Capecitabine—esophageal cancer	0.000205	0.000767	CcSEcCtD
Fluoxetine—Dermatitis—Cisplatin—esophageal cancer	0.000205	0.000767	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000203	0.000759	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—esophageal cancer	0.000202	0.000756	CcSEcCtD
Fluoxetine—Feeling abnormal—Capecitabine—esophageal cancer	0.000197	0.000739	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—esophageal cancer	0.000197	0.000738	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—esophageal cancer	0.000196	0.000735	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000196	0.000734	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—esophageal cancer	0.000196	0.000732	CcSEcCtD
Fluoxetine—Nausea—Cisplatin—esophageal cancer	0.000193	0.000723	CcSEcCtD
Fluoxetine—Cough—Methotrexate—esophageal cancer	0.000191	0.000714	CcSEcCtD
Fluoxetine—Urticaria—Capecitabine—esophageal cancer	0.00019	0.000713	CcSEcCtD
Fluoxetine—Body temperature increased—Capecitabine—esophageal cancer	0.000189	0.000709	CcSEcCtD
Fluoxetine—Abdominal pain—Capecitabine—esophageal cancer	0.000189	0.000709	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—esophageal cancer	0.000189	0.000709	CcSEcCtD
Fluoxetine—CYP2B6—bronchus—esophageal cancer	0.000186	0.0304	CbGeAlD
Fluoxetine—Myalgia—Methotrexate—esophageal cancer	0.000186	0.000697	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—esophageal cancer	0.000186	0.000697	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—esophageal cancer	0.000186	0.000697	CcSEcCtD
Fluoxetine—SLC6A4—lung—esophageal cancer	0.000185	0.0302	CbGeAlD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000185	0.000692	CcSEcCtD
Fluoxetine—SIGMAR1—lung—esophageal cancer	0.000184	0.03	CbGeAlD
Fluoxetine—CYP2C19—digestive system—esophageal cancer	0.000184	0.03	CbGeAlD
Fluoxetine—Discomfort—Methotrexate—esophageal cancer	0.000184	0.000688	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—esophageal cancer	0.00018	0.000673	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000178	0.000668	CcSEcCtD
Fluoxetine—Infection—Methotrexate—esophageal cancer	0.000177	0.000663	CcSEcCtD
Fluoxetine—Hypersensitivity—Capecitabine—esophageal cancer	0.000177	0.000661	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000175	0.000654	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—esophageal cancer	0.000173	0.000649	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000172	0.000646	CcSEcCtD
Fluoxetine—Asthenia—Capecitabine—esophageal cancer	0.000172	0.000644	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—esophageal cancer	0.00017	0.000637	CcSEcCtD
Fluoxetine—Pruritus—Capecitabine—esophageal cancer	0.00017	0.000635	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—esophageal cancer	0.000167	0.000624	CcSEcCtD
Fluoxetine—Diarrhoea—Capecitabine—esophageal cancer	0.000164	0.000614	CcSEcCtD
Fluoxetine—SLC6A2—lung—esophageal cancer	0.000163	0.0266	CbGeAlD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000163	0.000608	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—esophageal cancer	0.000161	0.000604	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—esophageal cancer	0.00016	0.0006	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—esophageal cancer	0.000159	0.000595	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—esophageal cancer	0.000159	0.000594	CcSEcCtD
Fluoxetine—Dizziness—Capecitabine—esophageal cancer	0.000158	0.000593	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—esophageal cancer	0.000157	0.000588	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—esophageal cancer	0.000155	0.000581	CcSEcCtD
Fluoxetine—HTR2A—epithelium—esophageal cancer	0.000154	0.0252	CbGeAlD
Fluoxetine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000154	0.000577	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—esophageal cancer	0.000154	0.000576	CcSEcCtD
Fluoxetine—Pain—Methotrexate—esophageal cancer	0.000153	0.000571	CcSEcCtD
Fluoxetine—Vomiting—Capecitabine—esophageal cancer	0.000152	0.00057	CcSEcCtD
Fluoxetine—Rash—Capecitabine—esophageal cancer	0.000151	0.000566	CcSEcCtD
Fluoxetine—Dermatitis—Capecitabine—esophageal cancer	0.000151	0.000565	CcSEcCtD
Fluoxetine—CYP1A2—digestive system—esophageal cancer	0.00015	0.0245	CbGeAlD
Fluoxetine—Headache—Capecitabine—esophageal cancer	0.00015	0.000562	CcSEcCtD
Fluoxetine—ORM1—lymph node—esophageal cancer	0.000149	0.0242	CbGeAlD
Fluoxetine—HTR2A—smooth muscle tissue—esophageal cancer	0.000149	0.0242	CbGeAlD
Fluoxetine—Feeling abnormal—Methotrexate—esophageal cancer	0.000147	0.00055	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000146	0.000546	CcSEcCtD
Fluoxetine—CYP3A5—digestive system—esophageal cancer	0.000145	0.0236	CbGeAlD
Fluoxetine—CYP2B6—digestive system—esophageal cancer	0.000144	0.0235	CbGeAlD
Fluoxetine—CYP2C9—digestive system—esophageal cancer	0.000143	0.0232	CbGeAlD
Fluoxetine—Nausea—Capecitabine—esophageal cancer	0.000142	0.000533	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—esophageal cancer	0.000142	0.000531	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—esophageal cancer	0.000141	0.000528	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—esophageal cancer	0.000141	0.000528	CcSEcCtD
Fluoxetine—HTR2A—trachea—esophageal cancer	0.000137	0.0222	CbGeAlD
Fluoxetine—Hypersensitivity—Methotrexate—esophageal cancer	0.000131	0.000492	CcSEcCtD
Fluoxetine—ALB—lymph node—esophageal cancer	0.000131	0.0213	CbGeAlD
Fluoxetine—Asthenia—Methotrexate—esophageal cancer	0.000128	0.000479	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—esophageal cancer	0.000126	0.000472	CcSEcCtD
Fluoxetine—SIGMAR1—lymph node—esophageal cancer	0.000126	0.0205	CbGeAlD
Fluoxetine—CYP1A2—lung—esophageal cancer	0.000126	0.0204	CbGeAlD
Fluoxetine—Diarrhoea—Methotrexate—esophageal cancer	0.000122	0.000457	CcSEcCtD
Fluoxetine—CYP3A5—lung—esophageal cancer	0.000121	0.0197	CbGeAlD
Fluoxetine—CYP2B6—lung—esophageal cancer	0.00012	0.0196	CbGeAlD
Fluoxetine—Dizziness—Methotrexate—esophageal cancer	0.000118	0.000442	CcSEcCtD
Fluoxetine—HTR2A—digestive system—esophageal cancer	0.000117	0.0191	CbGeAlD
Fluoxetine—Vomiting—Methotrexate—esophageal cancer	0.000113	0.000425	CcSEcCtD
Fluoxetine—Rash—Methotrexate—esophageal cancer	0.000112	0.000421	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—esophageal cancer	0.000112	0.000421	CcSEcCtD
Fluoxetine—Headache—Methotrexate—esophageal cancer	0.000112	0.000418	CcSEcCtD
Fluoxetine—SLC6A2—lymph node—esophageal cancer	0.000112	0.0182	CbGeAlD
Fluoxetine—CYP3A4—digestive system—esophageal cancer	0.000109	0.0177	CbGeAlD
Fluoxetine—CYP2D6—digestive system—esophageal cancer	0.000107	0.0174	CbGeAlD
Fluoxetine—Nausea—Methotrexate—esophageal cancer	0.000106	0.000397	CcSEcCtD
Fluoxetine—ABCB1—epithelium—esophageal cancer	0.000101	0.0165	CbGeAlD
Fluoxetine—HTR2A—lung—esophageal cancer	9.81e-05	0.016	CbGeAlD
Fluoxetine—ABCB1—trachea—esophageal cancer	8.95e-05	0.0146	CbGeAlD
Fluoxetine—ABCB1—digestive system—esophageal cancer	7.7e-05	0.0125	CbGeAlD
Fluoxetine—ABCB1—lung—esophageal cancer	6.43e-05	0.0105	CbGeAlD
Fluoxetine—ABCB1—lymph node—esophageal cancer	4.4e-05	0.00716	CbGeAlD
Fluoxetine—CYP2B6—Metabolism—PSME2—esophageal cancer	2.41e-05	0.000152	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PSME1—esophageal cancer	2.41e-05	0.000152	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS1—esophageal cancer	2.39e-05	0.000151	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ENO1—esophageal cancer	2.39e-05	0.000151	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALDOB—esophageal cancer	2.38e-05	0.00015	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—CREBBP—esophageal cancer	2.37e-05	0.00015	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CA1—esophageal cancer	2.37e-05	0.00015	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.37e-05	0.00015	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PSME2—esophageal cancer	2.36e-05	0.000149	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PSME1—esophageal cancer	2.36e-05	0.000149	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PSME2—esophageal cancer	2.35e-05	0.000148	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PSME1—esophageal cancer	2.35e-05	0.000148	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	2.35e-05	0.000148	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GAPDH—esophageal cancer	2.34e-05	0.000148	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TPI1—esophageal cancer	2.34e-05	0.000147	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.34e-05	0.000147	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CRABP1—esophageal cancer	2.32e-05	0.000147	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	2.32e-05	0.000146	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTO1—esophageal cancer	2.32e-05	0.000146	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TPI1—esophageal cancer	2.32e-05	0.000146	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ALDH2—esophageal cancer	2.31e-05	0.000146	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH2—esophageal cancer	2.3e-05	0.000145	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ADH1B—esophageal cancer	2.29e-05	0.000145	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GAPDH—esophageal cancer	2.29e-05	0.000144	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SST—esophageal cancer	2.28e-05	0.000144	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.28e-05	0.000144	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CRABP1—esophageal cancer	2.27e-05	0.000143	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.24e-05	0.000141	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GHRL—esophageal cancer	2.23e-05	0.00014	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	2.23e-05	0.00014	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.22e-05	0.00014	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GNG7—esophageal cancer	2.21e-05	0.000139	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.21e-05	0.000139	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTT1—esophageal cancer	2.19e-05	0.000138	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	2.19e-05	0.000138	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMP—esophageal cancer	2.19e-05	0.000138	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP2A6—esophageal cancer	2.17e-05	0.000137	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CA2—esophageal cancer	2.17e-05	0.000137	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.16e-05	0.000136	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GNG7—esophageal cancer	2.16e-05	0.000136	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.16e-05	0.000136	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.14e-05	0.000135	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.14e-05	0.000135	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	2.13e-05	0.000134	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NOS3—esophageal cancer	2.13e-05	0.000134	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.12e-05	0.000134	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP1B1—esophageal cancer	2.08e-05	0.000131	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALOX15—esophageal cancer	2.08e-05	0.000131	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.07e-05	0.000131	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS1—esophageal cancer	2.06e-05	0.00013	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ENO1—esophageal cancer	2.06e-05	0.00013	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.05e-05	0.00013	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	2.04e-05	0.000129	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GNG7—esophageal cancer	2.03e-05	0.000128	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	2.03e-05	0.000128	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PSME2—esophageal cancer	2.03e-05	0.000128	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PSME1—esophageal cancer	2.03e-05	0.000128	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALDH2—esophageal cancer	2.02e-05	0.000128	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.02e-05	0.000127	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ADH7—esophageal cancer	2.02e-05	0.000127	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GNG7—esophageal cancer	2.02e-05	0.000127	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	2e-05	0.000126	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TPI1—esophageal cancer	1.98e-05	0.000125	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.98e-05	0.000125	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTT1—esophageal cancer	1.97e-05	0.000124	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP19A1—esophageal cancer	1.95e-05	0.000123	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1.95e-05	0.000123	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.94e-05	0.000122	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	1.93e-05	0.000122	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTT1—esophageal cancer	1.92e-05	0.000121	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.91e-05	0.00012	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.91e-05	0.00012	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.9e-05	0.00012	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.9e-05	0.00012	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.89e-05	0.000119	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ENO1—esophageal cancer	1.85e-05	0.000116	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.85e-05	0.000116	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.83e-05	0.000115	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PSME2—esophageal cancer	1.82e-05	0.000115	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PSME1—esophageal cancer	1.82e-05	0.000115	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.81e-05	0.000114	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.81e-05	0.000114	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS1—esophageal cancer	1.8e-05	0.000114	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ENO1—esophageal cancer	1.8e-05	0.000114	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.8e-05	0.000114	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.8e-05	0.000113	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.79e-05	0.000113	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.78e-05	0.000112	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.78e-05	0.000112	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PSME1—esophageal cancer	1.78e-05	0.000112	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PSME2—esophageal cancer	1.78e-05	0.000112	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	1.77e-05	0.000112	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.77e-05	0.000112	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.77e-05	0.000112	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.77e-05	0.000112	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1B1—esophageal cancer	1.75e-05	0.00011	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.74e-05	0.00011	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GNG7—esophageal cancer	1.72e-05	0.000109	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.71e-05	0.000108	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.7e-05	0.000107	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ENO1—esophageal cancer	1.7e-05	0.000107	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMP—esophageal cancer	1.69e-05	0.000107	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ENO1—esophageal cancer	1.68e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.68e-05	0.000106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	1.68e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PSME1—esophageal cancer	1.67e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PSME2—esophageal cancer	1.67e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.67e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PSME2—esophageal cancer	1.66e-05	0.000105	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PSME1—esophageal cancer	1.66e-05	0.000105	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP19A1—esophageal cancer	1.64e-05	0.000104	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.64e-05	0.000104	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—EP300—esophageal cancer	1.62e-05	0.000102	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.61e-05	0.000102	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.6e-05	0.000101	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.59e-05	0.0001	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	1.58e-05	9.97e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.57e-05	9.91e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.54e-05	9.69e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.53e-05	9.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TPI1—esophageal cancer	1.53e-05	9.64e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.53e-05	9.64e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.52e-05	9.58e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.51e-05	9.54e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KDR—esophageal cancer	1.51e-05	9.54e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—HMOX1—esophageal cancer	1.5e-05	9.47e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.48e-05	9.31e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.47e-05	9.29e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.46e-05	9.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.45e-05	9.14e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.44e-05	9.11e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.44e-05	9.09e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ABCB1—esophageal cancer	1.44e-05	9.09e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ENO1—esophageal cancer	1.44e-05	9.08e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.44e-05	9.08e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.43e-05	9.03e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	1.42e-05	8.98e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSME1—esophageal cancer	1.42e-05	8.94e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSME2—esophageal cancer	1.42e-05	8.94e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.41e-05	8.9e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.4e-05	8.82e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	1.37e-05	8.66e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.36e-05	8.57e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.35e-05	8.5e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.35e-05	8.49e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GNG7—esophageal cancer	1.33e-05	8.39e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.32e-05	8.34e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—HMOX1—esophageal cancer	1.31e-05	8.29e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KDR—esophageal cancer	1.31e-05	8.28e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.29e-05	8.16e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.29e-05	8.14e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.27e-05	8e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.25e-05	7.86e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.24e-05	7.82e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.24e-05	7.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.24e-05	7.8e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.23e-05	7.75e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.22e-05	7.72e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.21e-05	7.65e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.2e-05	7.6e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—esophageal cancer	1.2e-05	7.55e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.19e-05	7.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.18e-05	7.48e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.18e-05	7.44e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.17e-05	7.39e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—esophageal cancer	1.16e-05	7.3e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.16e-05	7.29e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.15e-05	7.26e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.14e-05	7.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.12e-05	7.07e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.12e-05	7.05e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO1—esophageal cancer	1.11e-05	7.01e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.11e-05	7.01e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.1e-05	6.95e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.1e-05	6.95e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSME1—esophageal cancer	1.09e-05	6.9e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSME2—esophageal cancer	1.09e-05	6.9e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.09e-05	6.87e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.08e-05	6.82e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.05e-05	6.64e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.05e-05	6.62e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.03e-05	6.5e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NOS3—esophageal cancer	1.02e-05	6.46e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.01e-05	6.36e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1e-05	6.33e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NOS3—esophageal cancer	1e-05	6.31e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.77e-06	6.17e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CREBBP—esophageal cancer	9.62e-06	6.07e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	9.56e-06	6.03e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	9.55e-06	6.03e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	9.44e-06	5.96e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	9.39e-06	5.92e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—esophageal cancer	9.36e-06	5.91e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	9.24e-06	5.83e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—esophageal cancer	9.15e-06	5.77e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.91e-06	5.62e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	8.88e-06	5.6e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EP300—esophageal cancer	8.79e-06	5.55e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CREBBP—esophageal cancer	8.64e-06	5.45e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NOS3—esophageal cancer	8.62e-06	5.44e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CREBBP—esophageal cancer	8.43e-06	5.32e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	8.29e-06	5.23e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMOX1—esophageal cancer	8.1e-06	5.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	8.02e-06	5.06e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CREBBP—esophageal cancer	7.95e-06	5.01e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—esophageal cancer	7.88e-06	4.97e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CREBBP—esophageal cancer	7.88e-06	4.97e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—EP300—esophageal cancer	7.79e-06	4.91e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—esophageal cancer	7.77e-06	4.91e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NOS3—esophageal cancer	7.74e-06	4.88e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—esophageal cancer	7.66e-06	4.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EP300—esophageal cancer	7.63e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.62e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—EP300—esophageal cancer	7.61e-06	4.8e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NOS3—esophageal cancer	7.55e-06	4.76e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	7.49e-06	4.73e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NOS3—esophageal cancer	7.11e-06	4.49e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—esophageal cancer	7.07e-06	4.46e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NOS3—esophageal cancer	7.05e-06	4.45e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—esophageal cancer	6.91e-06	4.36e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CREBBP—esophageal cancer	6.73e-06	4.25e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—esophageal cancer	6.65e-06	4.2e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—EP300—esophageal cancer	6.55e-06	4.14e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.51e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	6.51e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	6.5e-06	4.1e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—esophageal cancer	6.45e-06	4.07e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—esophageal cancer	6.29e-06	3.97e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NOS3—esophageal cancer	6.03e-06	3.8e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—EP300—esophageal cancer	5.88e-06	3.71e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—esophageal cancer	5.76e-06	3.63e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—EP300—esophageal cancer	5.74e-06	3.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	5.65e-06	3.56e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	5.63e-06	3.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.51e-06	3.48e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—esophageal cancer	5.46e-06	3.45e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—EP300—esophageal cancer	5.41e-06	3.41e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—EP300—esophageal cancer	5.37e-06	3.39e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.2e-06	3.28e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—esophageal cancer	4.85e-06	3.06e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NOS3—esophageal cancer	4.65e-06	2.94e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—EP300—esophageal cancer	4.58e-06	2.89e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.35e-06	2.75e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.25e-06	2.68e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.25e-06	2.68e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4e-06	2.53e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.97e-06	2.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—EP300—esophageal cancer	3.54e-06	2.23e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.39e-06	2.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.62e-06	1.65e-05	CbGpPWpGaD
